Sanjay Kharche

We are MVT in Silico who deploy fundamental scientific principles to build effective medical treatments.

There is a high failure rate in the development of medical treatments from discovery stage to market. A major reason for this is our lack of understanding of the system that the treatment is intended to treat.

We use computer modelling & simulation to understand the system that the treatment is intended to treat. To do so, we have developed our proprietary software called “MVT Software Suite.” that has modules that are capable of simulating the system from the molecular level to the whole body level to digital clinical trials.

MVT in Silico Corp. (MVTIS) is a DeepTech company within the life sciences industry whose proprietary bioengineering software suite and proprietary non-animal models accelerate the pace of medical technology R&D, reduces prototyping expenditure, and reduces time to regulatory approval. In the process, MVTIS is developing its own intellectual property assets. Our mid-term ambition is to become a medical technology (MedTech implantable medical devices, BioPharma) manufacturer and penetrate global markets.

The sectors we serve are:
Hypertension, obesity, and aging.
FemTech.
Drug delivery systems.
Biophysical and physiological evidence generation for regulatory approval.

Our services and products are for collaborations and internal pipelines.
CAD modelling.
FEA analysis.
CFD simulations.
Genetics.
Molecular simulations.
Bespoke biophysical computer models.
Non animal models: lab on a chip (microfluidic devices).
Original and curated+annotated data repositories.

As of January 2025, we are working with three companies and three university research groups. We are funded by an initial founder’s investment and government grants.